YAKUGAKU ZASSHI
Online ISSN : 1347-5231
Print ISSN : 0031-6903
ISSN-L : 0031-6903
Syntheses and Central Depressant Activity in Mice of Uracil Derivatives. Studies on Development of New Sedative-Hypnotics.II
Yuji TATEOKAShigeki HIRAMURANoriyuki USAMIToshiyuki KIMURAKazuhito WATANABEIkuo YAMAMOTO
Author information
JOURNAL FREE ACCESS

1992 Volume 112 Issue 7 Pages 470-478

Details
Abstract
Fifteen kinds of uracil derivatives, which were substituted with functional groups such as benzyl (Bn), methoxymethyl (MOM), n-propyl (Pr) or allyl (A) group at the N1 and/or N8 position of uracil, were synthesized. Sedative-hypnotic activity, pentobarbital (PB)-induced sleep prolongation and acute toxicity as indices of their pharmacological activities were evaluated using mice. Spontaneous activities of mice treated with N1-benzyluracil (N1-BnU, 7), N8-benzyluracil (N8-BnU, 8), N1, N8-dibenzyluracil (DBnU, 9), N1-benzyl-N8-allyluracil (BnAU, 14) and N1-allyl-N8-benzyluracil (ABnU, 15) were measured. Ten kinds of uracil derivatives showed hypnotic activity. ED50's values of ABnU (15) and N1-propyl-N8-benzyluracil (PrBnU, 13) were 155 and 172 mg/kg, i.p., respectively. Those effects were more potent than that of barbital (179 mg/kg, i.p.). Ten kinds of uracil derivatives tested significantly prolonged the PB-induced sleeping time. N8-BnU (8) increased the spontaneous activity of mice at a dose of 80 mg/kg, i.p., while ABnU (15) depressed the spontaneous activity at a dose of 160 mg/kg, i.p. The other compounds did not show any significant effect on the spontaneous activity of mice. LD50's values of ABnU (15), PrBnU (13) and N1-methoxymethyl-N8-benzyluracil (MOMBnU, 11) were 199, 229 and 363mg/kg, i.p., respectively. LD50's values of the other derivatives were more than 480 mg/kg, i.p. These results indicate that the benzyl group at the N8 position of uracil is important for exhibiting sedative-hypnotic activity of uracil derivatives, and that ABnU (15) has the most potent central depressant activity among the uracil derivatives tested.
Content from these authors
© by the PHARMACEUTICAL SOCIETY OF JAPAN
Previous article Next article
feedback
Top